Joseph Szulczewski, David Inman, Kevin Eliceiri, and Patricia Keely, Carbone Cancer Center at the Univ. of Wisconsin, National Cancer Institute, National Institutes of Health
EDITOR'S CHOICE IN CANCER IMMUNOTHERAPY
Y. Nie et al., “Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer,” Sci Signaling, 11:eaan0790, 2018.
Cancers are notorious for creating a no-fly zone around themselves—called the immunosuppressive tumor microenvironment—that is hostile to immunotherapy treatments. Determining ways to turn off immunosuppressive actors such as tumor-infiltrating regulatory T cells (Tregs) is vital to making immunotherapies more effective.
FRIEND OR FOE?
Conventional wisdom has long held that tumor necrosis factor (TNF) receptor type II (TNFR2) downregulates Treg function, says Xin Chen, a cancer researcher at the University of Macau. But his group...